Last reviewed 2026-04-19 · How we verify

CICAPROST

Phase 2 active Small molecule

CICAPROST is a cicaprost drug. It is currently in Phase 2 development.

Cicaprost works by binding to and activating the prostacyclin receptor, mimicking the effects of prostacyclin to promote vasodilation and inhibit platelet aggregation.

Cicaprost is a small molecule drug that targets the prostacyclin receptor. It is classified as a cicaprost, a type of medication that works by mimicking the effects of prostacyclin, a naturally occurring substance in the body. However, its commercial status and approved indications are unknown. As a prostacyclin receptor agonist, cicaprost is likely used to treat conditions related to blood vessel constriction and inflammation. Further research is needed to determine its full potential and safety profile.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CICAPROST
Drug class	cicaprost
Target	Prostacyclin receptor, Prostaglandin D2 receptor, Prostaglandin E2 receptor EP1 subtype
Modality	Small molecule
Therapeutic area	Hematology
Phase	Phase 2

Mechanism of action

Imagine your blood vessels are like roads in your body. Prostacyclin is like a traffic light that helps keep the roads open and flowing. Cicaprost is like a duplicate traffic light that helps keep the roads open and flowing, even when the original light is not working.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CICAPROST CI brief — competitive landscape report
CICAPROST updates RSS · CI watch RSS

Frequently asked questions about CICAPROST

What is CICAPROST?

CICAPROST is a cicaprost drug.

How does CICAPROST work?

Cicaprost works by binding to and activating the prostacyclin receptor, mimicking the effects of prostacyclin to promote vasodilation and inhibit platelet aggregation.

What drug class is CICAPROST in?

CICAPROST belongs to the cicaprost class. See all cicaprost drugs at /class/cicaprost.

What development phase is CICAPROST in?

CICAPROST is in Phase 2.

What does CICAPROST target?

CICAPROST targets Prostacyclin receptor, Prostaglandin D2 receptor, Prostaglandin E2 receptor EP1 subtype and is a cicaprost.

Drug class: All cicaprost drugs
Target: All drugs targeting Prostacyclin receptor, Prostaglandin D2 receptor, Prostaglandin E2 receptor EP1 subtype
Therapeutic area: All drugs in Hematology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing